#1 Clinical Trials Search in Europe

Caffeine Citrate

This article explores the use of caffeine citrate in various clinical trials, focusing on its applications in neonatal care for conditions like apnea of prematurity and respiratory distress syndrome. Additionally, it examines potential benefits for adult patients in areas such as postoperative delirium and liver disease. The trials investigate different dosing regimens, administration methods, and timing of caffeine citrate therapy to optimize its effectiveness and safety.

Table of Contents

What is Caffeine Citrate?

Caffeine citrate is a medication commonly used in neonatal intensive care units (NICUs) to treat premature infants. It is a stimulant drug that belongs to a class of medications called methylxanthines. Caffeine citrate is also known by brand names such as Cafcit, Peyona, and Neocaf[1][2].

Uses and Benefits

Caffeine citrate is primarily used to treat and prevent a condition called apnea of prematurity. This is a common problem in premature babies where they temporarily stop breathing for short periods. The medication helps stimulate the baby’s breathing and reduces the frequency of these apnea episodes[3].

Research has shown that caffeine citrate can provide several benefits for premature infants, including:

  • Reducing the need for mechanical ventilation (breathing machines)[4]
  • Decreasing the risk of bronchopulmonary dysplasia (a chronic lung condition in premature infants)[4]
  • Improving the chances of successful removal of breathing tubes (extubation)[5]
  • Potentially reducing the risk of cerebral palsy (a group of disorders affecting movement and muscle tone)[4]
  • Possibly improving long-term neurodevelopmental outcomes[4]

How It Works

Caffeine citrate works by stimulating the respiratory center in the brain, which controls breathing. It increases the baby’s sensitivity to carbon dioxide, a waste gas that triggers the urge to breathe. The medication also improves the function of the diaphragm, the main muscle used for breathing[1].

Additionally, caffeine citrate acts as an adenosine receptor antagonist. This means it blocks the effects of adenosine, a substance that can inhibit breathing. By doing so, caffeine helps maintain regular breathing patterns in premature infants[2].

Administration

Caffeine citrate is typically given to premature infants in one of two ways:

  1. Intravenously (IV): Through a small tube inserted into a vein[3]
  2. Orally: By mouth or through a feeding tube[6]

The timing of when to start caffeine treatment can vary. Some doctors may give it as a preventive measure soon after birth, while others may wait until the baby shows signs of apnea[7].

Dosage

The dosage of caffeine citrate can vary depending on the specific needs of the baby and the practices of the NICU. Generally, treatment starts with a loading dose followed by smaller maintenance doses. Common dosing regimens include:

  • Loading dose: 20-40 mg/kg (milligrams per kilogram of body weight)
  • Maintenance dose: 5-10 mg/kg per day[3][5]

Some studies are investigating whether higher doses might be more effective for certain infants[5].

Potential Side Effects

While caffeine citrate is generally considered safe for premature infants, it can have some side effects. These may include:

  • Increased heart rate
  • Elevated blood pressure
  • Feeding intolerance or reduced feeding
  • Increased urine output[3]

Doctors closely monitor babies receiving caffeine citrate to watch for these and other potential side effects.

Ongoing Research

Researchers continue to study caffeine citrate to better understand its effects and optimize its use. Current areas of investigation include:

  • Comparing different dosing regimens to find the most effective and safe approach[5]
  • Studying the long-term effects on brain development and function[2]
  • Investigating its potential protective effects on the kidneys in certain conditions[8]
  • Exploring its use in older patients for conditions like postoperative delirium[9]

These ongoing studies aim to further improve the care and outcomes for premature infants and potentially expand the use of caffeine citrate in medical treatment.

Aspect Details
Primary Uses Treatment of apnea of prematurity, reduction of mechanical ventilation need in premature infants
Administration Methods Intravenous, enteral (through feeding tube)
Dosing Strategies Loading dose followed by maintenance doses; various regimens being studied (e.g., 5-20 mg/kg/day)
Timing of Administration Prophylactic (within first 72 hours of life) vs. therapeutic (after apnea onset)
Neonatal Outcomes Studied Duration of respiratory support, incidence of apnea, brain development (MRI), neurodevelopmental outcomes
Adult Applications Reduction of postoperative delirium, improvement of cognitive function after surgery
Potential Mechanisms Stimulation of respiratory center, improved lung compliance, increased diaphragm contractility
Safety Considerations Monitoring for changes in heart rate, blood pressure, gastrointestinal function; long-term neurodevelopmental effects

FAQ

  • What is caffeine citrate used for in premature infants? Caffeine citrate is primarily used to treat apnea of prematurity, reduce the need for mechanical ventilation, and improve respiratory function in premature infants. It may also help protect against brain injury and improve neurodevelopmental outcomes.
  • How is caffeine citrate administered to infants? Caffeine citrate can be administered intravenously or enterally (through a feeding tube). The dosage and timing vary depending on the specific trial and treatment protocol, but typically involves a loading dose followed by maintenance doses.
  • Are there any potential benefits of caffeine citrate for adults? Some trials are exploring the use of caffeine citrate in adults to reduce postoperative delirium, improve cognitive function after surgery, and potentially inhibit certain enzymes involved in liver disease.
  • What are some of the outcomes measured in caffeine citrate trials? Trials measure various outcomes, including duration of respiratory support, incidence of apnea, brain development through MRI scans, neurodevelopmental outcomes, and in adults, cognitive function and quality of recovery after surgery.
  • Are there any risks associated with caffeine citrate use? While caffeine citrate is generally considered safe, some trials are investigating potential side effects, especially with higher doses. These may include changes in heart rate, blood pressure, and gastrointestinal function. Long-term effects on neurodevelopment are also being studied.

Ongoing Clinical Trials on Caffeine Citrate

  • Testing Caffeine Citrate for Reducing Breathing Support Needs in Premature Newborns with Primary Apnea

    Recruiting

    3 1 1 1
    Investigated drugs:
    Czechia

  • Study on the Effect of Caffeine Citrate for Patients with Extubation Failure and Bronchopulmonary Dysplasia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

  • Study on Blood Thinners Rivaroxaban, Clopidogrel, and Aspirin for Patients with Heart Defects Undergoing Closure Procedures

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Apnea of Prematurity: A condition in premature infants where they temporarily stop breathing for short periods, often requiring intervention.
  • Caffeine Citrate: A medication used to stimulate breathing in premature infants and treat apnea of prematurity.
  • Bronchopulmonary Dysplasia (BPD): A chronic lung disease that can affect premature infants who have received prolonged mechanical ventilation or oxygen therapy.
  • Intraventricular Hemorrhage (IVH): Bleeding inside or around the ventricles (fluid-filled areas) of the brain, which can occur in premature infants.
  • Necrotizing Enterocolitis (NEC): A serious intestinal disease that primarily affects premature infants, causing inflammation and damage to the intestines.
  • Retinopathy of Prematurity (ROP): An eye disorder that can occur in premature infants, affecting the development of blood vessels in the retina.
  • Neurodevelopmental Outcome: The long-term cognitive, motor, and behavioral development of a child, often assessed in follow-up studies of premature infants.
  • Diffusion Tensor Imaging (DTI): An MRI technique used to visualize and measure the structure of white matter in the brain.
  • Postoperative Delirium: A state of confusion and disorientation that can occur in patients after surgery, particularly in older adults.
  • Vascular Adhesion Protein-1 (VAP-1): An enzyme involved in inflammation and cell adhesion, which may play a role in liver disease.

References

  1. https://clinicaltrials.gov/study/NCT05393817
  2. https://clinicaltrials.gov/study/NCT00809055
  3. https://clinicaltrials.eu/trial/study-on-the-effect-of-caffeine-citrate-for-patients-with-extubation-failure-and-bronchopulmonary-dysplasia/
  4. https://clinicaltrials.gov/study/NCT04001712
  5. https://clinicaltrials.gov/study/NCT02103777
  6. https://clinicaltrials.gov/study/NCT04044976
  7. https://clinicaltrials.gov/study/NCT02677584
  8. https://clinicaltrials.gov/study/NCT05295784
  9. https://clinicaltrials.gov/study/NCT05574400